# A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

> **NCT04556526** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 4031 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.ZEBOV
- **BIOLOGICAL:** MVA-BN-Filo

## Key facts

- **NCT ID:** NCT04556526
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2023-03-02
- **Final completion:** 2023-03-02
- **Target enrollment:** 4031 (ACTUAL)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04556526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04556526, "A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04556526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*